贝伐珠单抗治疗新生血管性年龄相关性黄斑变性中视网膜下高反射物质的预后价值
该研究回顾了2011至2014年73例(73眼)连续初治中心受累新生血管性年龄相关性黄斑变性的病历,患者接受3次每月玻璃体内贝伐珠单抗注射后按需治疗。基线光谱域光学相干断层扫描显示,47眼(64.4%)存在中心性视网膜下高反射物质(SHRM)。单因素分析显示,视网膜内液存在、SHRM存在、高反射SHRM、边界清晰的SHRM和厚的SHRM对12个月视力有显著预测价值;多因素回归分析中,除高反射性外,上述参数均显著,其中边界清晰的SHRM是最具预测价值的基线参数。结论支持将SHRM作为预后生物标志物。
要点
- 基线中心性SHRM存在、边界清晰的SHRM、视网膜内液和较厚的SHRM预测玻璃体内贝伐珠单抗治疗1年后视力较差。
- 多因素回归分析中,高反射性SHRM对12个月视力的预测价值未达统计学显著。
- 边界清晰的SHRM是最具预测价值的基线参数。
核心结论
- 本研究支持将SHRM作为解读新生血管性年龄相关性黄斑变性光学相干断层扫描时的预后生物标志物。
- 预测玻璃体内贝伐珠单抗治疗1年后视力较差的基线参数为:中心性SHRM存在、边界清晰的SHRM、视网膜内液和较厚的SHRM。
研究设计与样本
- 回顾性连续病例系列,纳入2011至2014年73例(73眼)初治中心受累新生血管性年龄相关性黄斑变性患者,接受3次每月玻璃体内贝伐珠单抗注射后按需治疗。
- 收集基线光谱域光学相干断层扫描SHRM参数(高度、宽度、面积、反射性、边界定义和均匀性)及新生血管活动性光学相干断层扫描生物标志物(视网膜内液、视网膜下液、视网膜体积、中心视网膜厚度和色素上皮脱离存在与否)。
主要发现
- 73眼中47眼(64.4%)基线存在中心性SHRM;平均年龄79.2±8.9岁。
- 平均最佳矫正视力(最小分辨角对数)在基线、3个月和12个月分别为0.70±0.57(20/100)、0.73±0.55(20/107)和0.76±0.63(20/115)。
- 单因素分析中,对12个月视力有显著预测价值的基线参数为:视网膜内液存在、SHRM存在、高反射SHRM、边界清晰的SHRM和厚的SHRM。
- 多因素回归分析中,除高反射性外,上述参数均显著;最具预测价值的基线参数为边界清晰的SHRM。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To study the correlation between subretinal hyperreflective material (SHRM) seen on spectral domain optical coherence tomography at baseline and visual outcomes after intravitreal bevacizumab injection in neovascular age-related macular degeneration. METHODS: Consecutive patient charts with treatment-naive center-involved neovascular age-related macular degeneration treated with 3 monthly intravitreal bevacizumab's, continued as needed, from 2011 to 2014 were reviewed. Baseline spectral domain optical coherence tomography SHRM parameters (height, width, area, reflectivity, border definition, and homogeneity) and established optical coherence tomography biomarkers of neovascular activity (intraretinal fluid, subretinal fluid, retinal volume, central retinal thickness, and pigment epithelial detachment presence) were collected. These baseline parameters were correlated with visual acuity at baseline, 3 and 12 months. RESULTS: Seventy-three eyes of 73 patients, 47 (64.4%) having central SHRM at baseline, were studied. Mean age was 79.2 ± 8.9 years. Mean best-corrected visual acuity was 0.70 ± 0.57 logarithm of the minimum angle of resolution (20/100), 0.73 ± 0.55 (20/107), and 0.76 ± 0.63 (20/115) at baseline, 3 and 12 months, respectively. Baseline parameters with a significant predictive value of 12-month visual acuity by univariate analysis were presence of intraretinal fluid, presence of SHRM, highly reflective SHRM, well-defined SHRM borders, and thick SHRM. These parameters, with the exception of high reflectivity, were significant on multivariate regression analysis. The most predictive baseline parameter was well-defined SHRM borders. CONCLUSION: This study supports the use of SHRM as a prognostic biomarker when interpreting optical coherence tomography in neovascular age-related macular degeneration. Baseline parameters predicting poorer vision 1 year after intravitreal bevacizumab treatment were as follows: presence of central SHRM, well-defined SHRM borders, intraretinal fluid, and thicker SHRM.
引用
- Pokroy R, Mimouni M, Barayev E, et al. PROGNOSTIC VALUE OF SUBRETINAL HYPERREFLECTIVE MATERIAL IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH BEVACIZUMAB. Retina. 2018. PMID: 28654630. doi:10.1097/IAE.0000000000001748
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。